Cargando…
Influenza epidemiology and influenza vaccine effectiveness during the 2016–2017 season in the Global Influenza Hospital Surveillance Network (GIHSN)
BACKGROUND: The Global Influenza Hospital Surveillance Network (GIHSN) aims to determine the burden of severe influenza disease and Influenza Vaccine Effectiveness (IVE). This is a prospective, active surveillance and hospital-based epidemiological study to collect epidemiological data in the GIHSN....
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498567/ https://www.ncbi.nlm.nih.gov/pubmed/31046725 http://dx.doi.org/10.1186/s12889-019-6713-5 |
_version_ | 1783415637715976192 |
---|---|
author | Baselga-Moreno, Víctor Trushakova, Svetlana McNeil, Shelly Sominina, Anna Nunes, Marta C. Draganescu, Anca Unal, Serhat Koul, Parvaiz Kyncl, Jan Zhang, Tao Kuatbayeva, Ainagul Ben-Salah, Afif Burtseva, Elena Puig-Barberà, Joan Díez-Domingo, Javier |
author_facet | Baselga-Moreno, Víctor Trushakova, Svetlana McNeil, Shelly Sominina, Anna Nunes, Marta C. Draganescu, Anca Unal, Serhat Koul, Parvaiz Kyncl, Jan Zhang, Tao Kuatbayeva, Ainagul Ben-Salah, Afif Burtseva, Elena Puig-Barberà, Joan Díez-Domingo, Javier |
author_sort | Baselga-Moreno, Víctor |
collection | PubMed |
description | BACKGROUND: The Global Influenza Hospital Surveillance Network (GIHSN) aims to determine the burden of severe influenza disease and Influenza Vaccine Effectiveness (IVE). This is a prospective, active surveillance and hospital-based epidemiological study to collect epidemiological data in the GIHSN. In the 2016–2017 influenza season, 15 sites in 14 countries participated in the GIHSN, although the analyses could not be performed in 2 sites. A common core protocol was used in order to make results comparable. Here we present the results of the GIHSN 2016–2017 influenza season. METHODS: A RT-PCR test was performed to all patients that accomplished the requirements detailed on a common core protocol. Patients admitted were included in the study after signing the informed consent, if they were residents, not institutionalised, not discharged in the previous 30 days from other hospitalisation with symptoms onset within the 7 days prior to admission. Patients 5 years old or more must also complied the Influenza-Like Illness definition. A test negative-design was implemented to perform IVE analysis. IVE was estimated using a logistic regression model, with the formula IVE = (1-aOR) × 100, where aOR is the adjusted Odds Ratio comparing cases and controls. RESULTS: Among 21,967 screened patients, 10,140 (46.16%) were included, as they accomplished the inclusion criteria, and tested, and therefore 11,827 (53.84%) patients were excluded. Around 60% of all patients included with laboratory results were recruited at 3 sites. The predominant strain was A(H3N2), detected in 63.6% of the cases (1840 patients), followed by B/Victoria, in 21.3% of the cases (618 patients). There were 2895 influenza positive patients (28.6% of the included patients). A(H1N1)pdm09 strain was mainly found in Mexico. IVE could only be performed in 6 sites separately. Overall IVE was 27.24 (95% CI 15.62–37.27. Vaccination seemed to confer better protection against influenza B and in people 2–4 years, or 85 years old or older. The aOR for hospitalized and testing positive for influenza was 3.02 (95% CI 1.59–5.76) comparing pregnant with non-pregnant women. CONCLUSIONS: Vaccination prevented around 1 in 4 hospitalisations with influenza. Sparse numbers didn’t allow estimating IVE in all sites separately. Pregnancy was found a risk factor for influenza, having 3 times more risk of being admitted with influenza for pregnant women. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12889-019-6713-5) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6498567 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-64985672019-05-09 Influenza epidemiology and influenza vaccine effectiveness during the 2016–2017 season in the Global Influenza Hospital Surveillance Network (GIHSN) Baselga-Moreno, Víctor Trushakova, Svetlana McNeil, Shelly Sominina, Anna Nunes, Marta C. Draganescu, Anca Unal, Serhat Koul, Parvaiz Kyncl, Jan Zhang, Tao Kuatbayeva, Ainagul Ben-Salah, Afif Burtseva, Elena Puig-Barberà, Joan Díez-Domingo, Javier BMC Public Health Research Article BACKGROUND: The Global Influenza Hospital Surveillance Network (GIHSN) aims to determine the burden of severe influenza disease and Influenza Vaccine Effectiveness (IVE). This is a prospective, active surveillance and hospital-based epidemiological study to collect epidemiological data in the GIHSN. In the 2016–2017 influenza season, 15 sites in 14 countries participated in the GIHSN, although the analyses could not be performed in 2 sites. A common core protocol was used in order to make results comparable. Here we present the results of the GIHSN 2016–2017 influenza season. METHODS: A RT-PCR test was performed to all patients that accomplished the requirements detailed on a common core protocol. Patients admitted were included in the study after signing the informed consent, if they were residents, not institutionalised, not discharged in the previous 30 days from other hospitalisation with symptoms onset within the 7 days prior to admission. Patients 5 years old or more must also complied the Influenza-Like Illness definition. A test negative-design was implemented to perform IVE analysis. IVE was estimated using a logistic regression model, with the formula IVE = (1-aOR) × 100, where aOR is the adjusted Odds Ratio comparing cases and controls. RESULTS: Among 21,967 screened patients, 10,140 (46.16%) were included, as they accomplished the inclusion criteria, and tested, and therefore 11,827 (53.84%) patients were excluded. Around 60% of all patients included with laboratory results were recruited at 3 sites. The predominant strain was A(H3N2), detected in 63.6% of the cases (1840 patients), followed by B/Victoria, in 21.3% of the cases (618 patients). There were 2895 influenza positive patients (28.6% of the included patients). A(H1N1)pdm09 strain was mainly found in Mexico. IVE could only be performed in 6 sites separately. Overall IVE was 27.24 (95% CI 15.62–37.27. Vaccination seemed to confer better protection against influenza B and in people 2–4 years, or 85 years old or older. The aOR for hospitalized and testing positive for influenza was 3.02 (95% CI 1.59–5.76) comparing pregnant with non-pregnant women. CONCLUSIONS: Vaccination prevented around 1 in 4 hospitalisations with influenza. Sparse numbers didn’t allow estimating IVE in all sites separately. Pregnancy was found a risk factor for influenza, having 3 times more risk of being admitted with influenza for pregnant women. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12889-019-6713-5) contains supplementary material, which is available to authorized users. BioMed Central 2019-05-02 /pmc/articles/PMC6498567/ /pubmed/31046725 http://dx.doi.org/10.1186/s12889-019-6713-5 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Baselga-Moreno, Víctor Trushakova, Svetlana McNeil, Shelly Sominina, Anna Nunes, Marta C. Draganescu, Anca Unal, Serhat Koul, Parvaiz Kyncl, Jan Zhang, Tao Kuatbayeva, Ainagul Ben-Salah, Afif Burtseva, Elena Puig-Barberà, Joan Díez-Domingo, Javier Influenza epidemiology and influenza vaccine effectiveness during the 2016–2017 season in the Global Influenza Hospital Surveillance Network (GIHSN) |
title | Influenza epidemiology and influenza vaccine effectiveness during the 2016–2017 season in the Global Influenza Hospital Surveillance Network (GIHSN) |
title_full | Influenza epidemiology and influenza vaccine effectiveness during the 2016–2017 season in the Global Influenza Hospital Surveillance Network (GIHSN) |
title_fullStr | Influenza epidemiology and influenza vaccine effectiveness during the 2016–2017 season in the Global Influenza Hospital Surveillance Network (GIHSN) |
title_full_unstemmed | Influenza epidemiology and influenza vaccine effectiveness during the 2016–2017 season in the Global Influenza Hospital Surveillance Network (GIHSN) |
title_short | Influenza epidemiology and influenza vaccine effectiveness during the 2016–2017 season in the Global Influenza Hospital Surveillance Network (GIHSN) |
title_sort | influenza epidemiology and influenza vaccine effectiveness during the 2016–2017 season in the global influenza hospital surveillance network (gihsn) |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498567/ https://www.ncbi.nlm.nih.gov/pubmed/31046725 http://dx.doi.org/10.1186/s12889-019-6713-5 |
work_keys_str_mv | AT baselgamorenovictor influenzaepidemiologyandinfluenzavaccineeffectivenessduringthe20162017seasonintheglobalinfluenzahospitalsurveillancenetworkgihsn AT trushakovasvetlana influenzaepidemiologyandinfluenzavaccineeffectivenessduringthe20162017seasonintheglobalinfluenzahospitalsurveillancenetworkgihsn AT mcneilshelly influenzaepidemiologyandinfluenzavaccineeffectivenessduringthe20162017seasonintheglobalinfluenzahospitalsurveillancenetworkgihsn AT somininaanna influenzaepidemiologyandinfluenzavaccineeffectivenessduringthe20162017seasonintheglobalinfluenzahospitalsurveillancenetworkgihsn AT nunesmartac influenzaepidemiologyandinfluenzavaccineeffectivenessduringthe20162017seasonintheglobalinfluenzahospitalsurveillancenetworkgihsn AT draganescuanca influenzaepidemiologyandinfluenzavaccineeffectivenessduringthe20162017seasonintheglobalinfluenzahospitalsurveillancenetworkgihsn AT unalserhat influenzaepidemiologyandinfluenzavaccineeffectivenessduringthe20162017seasonintheglobalinfluenzahospitalsurveillancenetworkgihsn AT koulparvaiz influenzaepidemiologyandinfluenzavaccineeffectivenessduringthe20162017seasonintheglobalinfluenzahospitalsurveillancenetworkgihsn AT kyncljan influenzaepidemiologyandinfluenzavaccineeffectivenessduringthe20162017seasonintheglobalinfluenzahospitalsurveillancenetworkgihsn AT zhangtao influenzaepidemiologyandinfluenzavaccineeffectivenessduringthe20162017seasonintheglobalinfluenzahospitalsurveillancenetworkgihsn AT kuatbayevaainagul influenzaepidemiologyandinfluenzavaccineeffectivenessduringthe20162017seasonintheglobalinfluenzahospitalsurveillancenetworkgihsn AT bensalahafif influenzaepidemiologyandinfluenzavaccineeffectivenessduringthe20162017seasonintheglobalinfluenzahospitalsurveillancenetworkgihsn AT burtsevaelena influenzaepidemiologyandinfluenzavaccineeffectivenessduringthe20162017seasonintheglobalinfluenzahospitalsurveillancenetworkgihsn AT puigbarberajoan influenzaepidemiologyandinfluenzavaccineeffectivenessduringthe20162017seasonintheglobalinfluenzahospitalsurveillancenetworkgihsn AT diezdomingojavier influenzaepidemiologyandinfluenzavaccineeffectivenessduringthe20162017seasonintheglobalinfluenzahospitalsurveillancenetworkgihsn AT influenzaepidemiologyandinfluenzavaccineeffectivenessduringthe20162017seasonintheglobalinfluenzahospitalsurveillancenetworkgihsn |